BR112020022062A2 - usos médicos - Google Patents

usos médicos Download PDF

Info

Publication number
BR112020022062A2
BR112020022062A2 BR112020022062-0A BR112020022062A BR112020022062A2 BR 112020022062 A2 BR112020022062 A2 BR 112020022062A2 BR 112020022062 A BR112020022062 A BR 112020022062A BR 112020022062 A2 BR112020022062 A2 BR 112020022062A2
Authority
BR
Brazil
Prior art keywords
patient
cells
antiviral agent
cell
fact
Prior art date
Application number
BR112020022062-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Hareth Nahi
Carl Arnold Gösta Gahrton
Evren Alici
Hans-Gustaf Einar Ljunggren
Original Assignee
XNK Therapeutics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by XNK Therapeutics AB filed Critical XNK Therapeutics AB
Publication of BR112020022062A2 publication Critical patent/BR112020022062A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112020022062-0A 2018-04-30 2019-04-30 usos médicos BR112020022062A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1807050.8A GB201807050D0 (en) 2018-04-30 2018-04-30 Medical uses
GB1807050.8 2018-04-30
PCT/EP2019/061122 WO2019211310A1 (en) 2018-04-30 2019-04-30 Medical uses

Publications (1)

Publication Number Publication Date
BR112020022062A2 true BR112020022062A2 (pt) 2021-02-02

Family

ID=62494975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020022062-0A BR112020022062A2 (pt) 2018-04-30 2019-04-30 usos médicos

Country Status (10)

Country Link
US (1) US20210186977A1 (cg-RX-API-DMAC7.html)
EP (1) EP3787685A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022522914A (cg-RX-API-DMAC7.html)
KR (1) KR102908831B1 (cg-RX-API-DMAC7.html)
CN (1) CN112399858A (cg-RX-API-DMAC7.html)
AU (1) AU2019264457B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020022062A2 (cg-RX-API-DMAC7.html)
CA (1) CA3097379A1 (cg-RX-API-DMAC7.html)
GB (1) GB201807050D0 (cg-RX-API-DMAC7.html)
WO (1) WO2019211310A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112168829B (zh) * 2020-09-24 2022-02-15 华南理工大学 抗病毒药物在制备治疗骨髓增生异常综合征药物中的应用及制得的骨髓增生异常综合征药物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016450A2 (en) * 2005-07-29 2007-02-08 Beth Israel Deaconess Medical Center Methods for treating or preventing reactivation of a latent herpesvirus infection
CN101506154B (zh) * 2006-08-21 2015-06-17 辛塔制药公司 用于治疗增生性疾病的化合物
US20090123442A1 (en) * 2007-11-09 2009-05-14 Avaris Ab Expanded nk cells
JP2012521215A (ja) * 2009-03-26 2012-09-13 アヴァリス・アクチエボラーグ Nk細胞の増殖
US20130011376A1 (en) * 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
JP5989016B2 (ja) * 2011-06-24 2016-09-07 国立大学法人九州大学 Nk細胞の増幅方法
JP6501264B2 (ja) * 2012-07-24 2019-04-17 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用
HK1246180A1 (zh) * 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
KR102416781B1 (ko) * 2015-08-20 2022-07-05 고려대학교 산학협력단 수두 대상포진 바이러스에 의해 유발되는 질병의 치료 또는 예방용 약학 조성물

Also Published As

Publication number Publication date
GB201807050D0 (en) 2018-06-13
CA3097379A1 (en) 2019-11-07
KR102908831B1 (ko) 2026-01-06
CN112399858A (zh) 2021-02-23
AU2019264457B2 (en) 2025-02-20
AU2019264457A1 (en) 2020-11-12
WO2019211310A1 (en) 2019-11-07
KR20210002690A (ko) 2021-01-08
EP3787685A1 (en) 2021-03-10
US20210186977A1 (en) 2021-06-24
JP2022522914A (ja) 2022-04-21

Similar Documents

Publication Publication Date Title
JP7654708B2 (ja) がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
US20250042922A1 (en) Kras modulating compounds
JP2022003043A (ja) 養子t細胞療法と腫瘍溶解性ウイルス補助療法とを組み合わせる方法
US9795604B2 (en) Methods of treating and preventing graft versus host disease
ES3036762T3 (en) A modulatable switch for selection of donor modified cells
TWI894135B (zh) 編碼ccl21之重組棒狀病毒
JP7239910B2 (ja) 治療剤、ならびに腫瘍および/またはがんの治療のための薬物のためのその使用
US20140255432A1 (en) Silvestrol, silvestrol analogs and uses thereof
CN122031489A (zh) 用于治疗肿瘤的方法和组合物
KR20170095270A (ko) 안정한 동결된 단순 포진 바이러스 제제
US20250122258A1 (en) Compositions and uses of vasoactive intestinal peptide (vip) antagonists
US12427184B2 (en) Treatment of immunosuppressed subjects
CN119816313A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
Jiang et al. Preclinical and clinical evaluation of intratumoral injection of an IL-12 expressing SKV-012 oncolytic virus for advanced solid tumors
CN111225672B (zh) 甲羟戊酸通路抑制剂及其药物组合物
AU2019264457B2 (en) Medical uses
CN108815188A (zh) 包含间充质干细胞制剂与免疫检查点抑制剂的肿瘤治疗组合物、试剂盒及其用途
HK40047175A (en) Medical uses
US20240115675A1 (en) Method of treating a tumor with a combination of an il-7 protein and a nucleotide vaccine
HK40119904A (en) Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)
WO2022048574A1 (zh) 一种编码Kras基因突变体的核酸分子

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]